1
|
Allam RM, El Kerdawy AM, Gouda AE, Ahmed KA, Abdel-Mohsen HT. Benzimidazole-oxindole hybrids as multi-kinase inhibitors targeting melanoma. Bioorg Chem 2024; 146:107243. [PMID: 38457953 DOI: 10.1016/j.bioorg.2024.107243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2023] [Revised: 02/15/2024] [Accepted: 02/24/2024] [Indexed: 03/10/2024]
Abstract
In the current study, a series of benzimidazole-oxindole conjugates 8a-t were designed and synthesized as type II multi-kinase inhibitors. They exhibited moderate to potent inhibitory activity against BRAFWT up to 99.61 % at 10 µM. Notably, compounds 8e, 8k, 8n and 8s demonstrated the most promising activity, with 99.44 to 99.61 % inhibition. Further evaluation revealed that 8e, 8k, 8n and 8s exhibit moderate to potent inhibitory effects on the kinases BRAFV600E, VEGFR-2, and FGFR-1. Additionally, compounds 8a-t were screened for their cytotoxicity by the NCI, and several compounds showed significant growth inhibition in diverse cancer cell lines. Compound 8e stood out with a GI50 range of 1.23 - 3.38 µM on melanoma cell lines. Encouraged by its efficacy, it was further investigated for its antitumor activity and mechanism of action, using sorafenib as a reference standard. The hybrid compound 8e exhibited potent cellular-level suppression of BRAFWT, VEGFR-2, and FGFR-1 in A375 cell line, surpassing the effects of sorafenib. In vivo studies demonstrate that 8e significantly inhibits the growth of B16F10 tumors in mice, leading to increased survival rates and histopathological tumor regression. Furthermore, 8e reduces angiogenesis markers, mRNA expression levels of VEGFR-2 and FGFR-1, and production of growth factors. It also downregulated Notch1 protein expression and decreased TGF-β1 production. Molecular docking simulations suggest that 8e binds as a promising type II kinase inhibitor in the target kinases interacting with the key regions in their kinase domain.
Collapse
Affiliation(s)
- Rasha M Allam
- Department of Pharmacology, Medical and Clinical Research Institute, National Research Centre, El-Buhouth St., Dokki, P.O. Box 12622, Cairo, Egypt
| | - Ahmed M El Kerdawy
- School of Pharmacy, College of Health and Science, University of Lincoln, Joseph Banks Laboratories, Green Lane, Lincoln, United Kingdom; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, P.O. Box 11562, Cairo, Egypt
| | - Ahmed E Gouda
- Pharmaceutical Research Department, Nawah Scientific, Cairo, Egypt
| | - Kawkab A Ahmed
- Pathology Department, Faculty of Veterinary Medicine, Cairo University, Giza, 12211, Egypt
| | - Heba T Abdel-Mohsen
- Chemistry of Natural and Microbial Products Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, El-Buhouth St., Dokki, P.O. Box 12622, Cairo, Egypt.
| |
Collapse
|
2
|
Abdel-Mohsen HT, Ibrahim MA, Nageeb AM, El Kerdawy AM. Receptor-based pharmacophore modeling, molecular docking, synthesis and biological evaluation of novel VEGFR-2, FGFR-1, and BRAF multi-kinase inhibitors. BMC Chem 2024; 18:42. [PMID: 38395926 PMCID: PMC10893631 DOI: 10.1186/s13065-024-01135-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2024] [Accepted: 02/05/2024] [Indexed: 02/25/2024] Open
Abstract
A receptor-based pharmacophore model describing the binding features required for the multi-kinase inhibition of the target kinases (VEGFR-2, FGFR-1, and BRAF) were constructed and validated. It showed a good overall quality in discriminating between the active and the inactive in a compiled test set compounds with F1 score of 0.502 and Mathew's correlation coefficient of 0.513. It described the ligand binding to the hinge region Cys or Ala, the glutamate residue of the Glu-Lys αC helix conserved pair, the DFG motif Asp at the activation loop, and the allosteric back pocket next to the ATP binding site. Moreover, excluded volumes were used to define the steric extent of the binding sites. The application of the developed pharmacophore model in virtual screening of an in-house scaffold dataset resulted in the identification of a benzimidazole-based scaffold as a promising hit within the dataset. Compounds 8a-u were designed through structural optimization of the hit benzimidazole-based scaffold through (un)substituted aryl substitution on 2 and 5 positions of the benzimidazole ring. Molecular docking simulations and ADME properties predictions confirmed the promising characteristics of the designed compounds in terms of binding affinity and pharmacokinetic properties, respectively. The designed compounds 8a-u were synthesized, and they demonstrated moderate to potent VEGFR-2 inhibitory activity at 10 µM. Compound 8u exhibited a potent inhibitory activity against the target kinases (VEGFR-2, FGFR-1, and BRAF) with IC50 values of 0.93, 3.74, 0.25 µM, respectively. The benzimidazole derivatives 8a-u were all selected by the NCI (USA) to conduct their anti-proliferation screening. Compounds 8a and 8d resulted in a potent mean growth inhibition % (GI%) of 97.73% and 92.51%, respectively. Whereas compounds 8h, 8j, 8k, 8o, 8q, 8r, and 8u showed a mean GI% > 100% (lethal effect). The most potent compounds on the NCI panel of 60 different cancer cell lines were progressed further to NCI five-dose testing. The benzimidazole derivatives 8a, 8d, 8h, 8j, 8k, 8o, 8q, 8r and 8u exhibited potent anticancer activity on the tested cell lines reaching sub-micromolar range. Moreover, 8u was found to induce cell cycle arrest of MCF-7 cell line at the G2/M phase and accumulating cells at the sub-G1 phase as a result of cell apoptosis.
Collapse
Affiliation(s)
- Heba T Abdel-Mohsen
- Chemistry of Natural and Microbial Products Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Dokki, P.O. 12622, Cairo, Egypt.
| | - Marwa A Ibrahim
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, P.O. 11562, Cairo, Egypt
| | - Amira M Nageeb
- High Throughput Molecular and Genetic Technology Lab, Center of Excellence for Advanced Sciences, Biochemistry Department, Biotechnology Research Institute, National Research Centre, Dokki, P.O. 12622, Cairo, Egypt
| | - Ahmed M El Kerdawy
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, P.O. 11562, Cairo, Egypt
- School of Pharmacy, College of Health and Science, University of Lincoln, Joseph Banks Laboratories, Green Lane, Lincoln, Lincolnshire, UK
| |
Collapse
|
3
|
Ali S, Ali M, Khan A, Ullah S, Waqas M, Al-Harrasi A, Latif A, Ahmad M, Saadiq M. Novel 5-(Arylideneamino)-1 H-Benzo[ d]imidazole-2-thiols as Potent Anti-Diabetic Agents: Synthesis, In Vitro α-Glucosidase Inhibition, and Molecular Docking Studies. ACS OMEGA 2022; 7:43468-43479. [PMID: 36506132 PMCID: PMC9730482 DOI: 10.1021/acsomega.2c03854] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/20/2022] [Accepted: 11/07/2022] [Indexed: 06/17/2023]
Abstract
A novel series of multifunctional benzimidazoles has been reported as potent inhibitors of α-glucosidase. The procedure relies on the synthesis of 5-amino-1H-benzo[d]imidazole-2-thiol 5 via the multistep reaction through 2-nitroaniline 1, benzene-1,2-diamine 2, 1H-benzo[d]imidazole-2-thiol 3, and 5-nitro-1H-benzo[d]imidazole-2-thiol 4. Further treatment of 5 with aromatic aldehydes 6a-m provided access to the target 5-(arylideneamino)-1H-benzo[d]imidazole-2-thiols 7a-m. The results of the bioactivity assessment revealed all the compounds as excellent inhibitors of the enzyme (IC50 range: 0.64 ± 0.05 μM to 343.10 ± 1.62 μM) than acarbose (873.34 ± 1.21). Among them, 7i was the most active inhibitor (IC50: 0.64 ± 0.05 μM) followed by 7d (IC50: 5.34 ± 0.16 μM), 7f (IC50: 6.46 ± 0.30 μM), 7g (IC50: 8.62 ± 0.19 μM), 7c (IC50: 9.84 ± 0.08 μM), 7m (IC50: 11.09 ± 0.79 μM), 7a (IC50: 11.84 ± 0.26 μM), 7e (IC50: 16.38 ± 0.53 μM), 7j (IC50: 18.65 ± 0.74 μM), 7h (IC50: 20.73 ± 0.59 μM), 7b (IC50: 27.26 ± 0.30 μM), 7k (70.28 ± 1.52 μM) and finally 7l (IC50: 343.10 ± 1.62 μM). Molecular docking revealed important interactions with the enzyme, thereby supporting the experimental findings.
Collapse
Affiliation(s)
- Sardar Ali
- Department
of Chemistry, University of Malakand, Dir Lower, Chakdara 18800 Khyber
Pakhtunkhwa, Pakistan
| | - Mumtaz Ali
- Department
of Chemistry, University of Malakand, Dir Lower, Chakdara 18800 Khyber
Pakhtunkhwa, Pakistan
| | - Ajmal Khan
- Natural
and Medical Sciences Research Center, University of Nizwa, P.O. Box 33, Birkat Al Mauz, Nizwa 616, Oman
| | - Saeed Ullah
- Natural
and Medical Sciences Research Center, University of Nizwa, P.O. Box 33, Birkat Al Mauz, Nizwa 616, Oman
- H. E.
J Research Institute of Chemistry, International
Center for Chemical and Biological Sciences, University of Karachi, Karachi 75270, Pakistan
| | - Muhammad Waqas
- Natural
and Medical Sciences Research Center, University of Nizwa, P.O. Box 33, Birkat Al Mauz, Nizwa 616, Oman
- Department
of Biotechnology and Genetic Engineering, Hazara University, Mansehra 21120, Pakistan
| | - Ahmed Al-Harrasi
- Natural
and Medical Sciences Research Center, University of Nizwa, P.O. Box 33, Birkat Al Mauz, Nizwa 616, Oman
| | - Abdul Latif
- Department
of Chemistry, University of Malakand, Dir Lower, Chakdara 18800 Khyber
Pakhtunkhwa, Pakistan
| | - Manzoor Ahmad
- Department
of Chemistry, University of Malakand, Dir Lower, Chakdara 18800 Khyber
Pakhtunkhwa, Pakistan
| | - Muhammad Saadiq
- Department
of Chemistry, Bacha Khan University, Charsadda 18800 Khyber Pakhtunkhwa, Pakistan
| |
Collapse
|
4
|
Saadiq M, Uddin G, Latif A, Ali M, Akbar N, Ammara, Ali S, Ahmad M, Zahoor M, Khan A, Al-Harrasi A. Synthesis, Bioactivity Assessment, and Molecular Docking of Non-sulfonamide Benzimidazole-Derived N-Acylhydrazone Scaffolds as Carbonic Anhydrase-II Inhibitors. ACS OMEGA 2022; 7:705-715. [PMID: 35036737 PMCID: PMC8756595 DOI: 10.1021/acsomega.1c05362] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/27/2021] [Accepted: 12/06/2021] [Indexed: 04/06/2024]
Abstract
This research reports the synthesis of new benzimidazole-derived N-acylhydrazones (NAH), their characterization using various spectroscopic methods, and in vitro evaluation as potent carbonic anhydrase-II inhibitors. Among the target compounds (9-29), few showed higher inhibition than the standard acetazolamide (IC50: 18.6 ± 0.43 μM), for example, compound 9 (IC50: 13.3 ± 1.25 μM), 10 (IC50: 17.2 ± 1.24 μM), 12 (IC50: 14.6 ± 0.62 μM), and 15 (IC50: 14.5 ± 1.05 μM). Molecular docking was performed on the most active compounds, which revealed their binding interactions with the active site of the enzyme, thus supporting the experimental findings.
Collapse
Affiliation(s)
- Muhammad Saadiq
- Institute
of Chemical Sciences, University of Peshawar, Peshawar, Khyber Pakhtunkhwa 25120, Pakistan
| | - Ghias Uddin
- Institute
of Chemical Sciences, University of Peshawar, Peshawar, Khyber Pakhtunkhwa 25120, Pakistan
| | - Abdul Latif
- Department
of Chemistry, University of Malakand, Dir (Lower), Chakdara, Khyber
Pakhtunkhwa 18800, Pakistan
| | - Mumtaz Ali
- Department
of Chemistry, University of Malakand, Dir (Lower), Chakdara, Khyber
Pakhtunkhwa 18800, Pakistan
| | - Nazia Akbar
- Department
of Biotechnology & Genetic Engineering, Hazara University, Mansehra, Khyber Pakhtunkhwa, 21120, Pakistan
| | - Ammara
- Department
of Chemistry, University of Malakand, Dir (Lower), Chakdara, Khyber
Pakhtunkhwa 18800, Pakistan
| | - Sardar Ali
- Department
of Chemistry, University of Malakand, Dir (Lower), Chakdara, Khyber
Pakhtunkhwa 18800, Pakistan
| | - Manzoor Ahmad
- Department
of Chemistry, University of Malakand, Dir (Lower), Chakdara, Khyber
Pakhtunkhwa 18800, Pakistan
| | - Mohammad Zahoor
- Department
of Biochemistry, University of Malakand, Dir (Lower), Chakdara, Khyber
Pakhtunkhwa 18800, Pakistan
| | - Ajmal Khan
- UoN
Chair of Oman’s Medicinal Plants and Marine Natural Products, University of Nizwa, Nizwa 616, Sultanate
of Oman
| | - Ahmed Al-Harrasi
- UoN
Chair of Oman’s Medicinal Plants and Marine Natural Products, University of Nizwa, Nizwa 616, Sultanate
of Oman
| |
Collapse
|
5
|
Hu Z, Zhang M, Zhou Q, Xu X, Tang B. Domino synthesis of fully substituted pyridines by silver-catalyzed chemoselective hetero-dimerization of isocyanides. Org Chem Front 2020. [DOI: 10.1039/c9qo01333d] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
A silver-catalyzed hetero-dimerization of various vinyl isocyanides with isocyanoacetamides has been developed for the efficient and practical synthesis of fully substituted pyridines in a single operation.
Collapse
Affiliation(s)
- Zhongyan Hu
- College of Chemistry
- Chemical Engineering and Materials Science
- Key Laboratory of Molecular and Nano Probes
- Ministry of Education
- Shandong Normal University
| | - Mingyue Zhang
- College of Chemistry
- Chemical Engineering and Materials Science
- Key Laboratory of Molecular and Nano Probes
- Ministry of Education
- Shandong Normal University
| | - Qinghua Zhou
- College of Chemistry
- Chemical Engineering and Materials Science
- Key Laboratory of Molecular and Nano Probes
- Ministry of Education
- Shandong Normal University
| | - Xianxiu Xu
- College of Chemistry
- Chemical Engineering and Materials Science
- Key Laboratory of Molecular and Nano Probes
- Ministry of Education
- Shandong Normal University
| | - Bo Tang
- College of Chemistry
- Chemical Engineering and Materials Science
- Key Laboratory of Molecular and Nano Probes
- Ministry of Education
- Shandong Normal University
| |
Collapse
|
6
|
Wang L, Zhang Y, Zhang Q, Zhu G, Zhang Z, Duan C, Lu T, Tang W. Discovery of potent Pan-Raf inhibitors with increased solubility to overcome drug resistance. Eur J Med Chem 2019; 163:243-255. [DOI: 10.1016/j.ejmech.2018.11.033] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2018] [Revised: 11/10/2018] [Accepted: 11/14/2018] [Indexed: 01/07/2023]
|
7
|
Jana P, Patel N, Mukherjee T, Soppina V, Kanvah S. A “turn-on” Michler's ketone–benzimidazole fluorescent probe for selective detection of serum albumins. NEW J CHEM 2019. [DOI: 10.1039/c9nj01972c] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Enhanced emission and selective binding with albumins.
Collapse
Affiliation(s)
- Palash Jana
- Department of Chemistry
- Indian Institute of Technology Gandhinagar
- Palaj
- India
| | - Nishaben Patel
- Department of Biological Engineering
- Indian Institute of Technology Gandhinagar
- Palaj
- India
| | | | - Virupakshi Soppina
- Department of Biological Engineering
- Indian Institute of Technology Gandhinagar
- Palaj
- India
| | - Sriram Kanvah
- Department of Chemistry
- Indian Institute of Technology Gandhinagar
- Palaj
- India
| |
Collapse
|
8
|
Design, synthesis and biological evaluation of novel benzo-α-pyrone containing piperazine derivatives as potential BRAF V600E inhibitors. Bioorg Med Chem Lett 2016; 26:4983-4991. [PMID: 27634195 DOI: 10.1016/j.bmcl.2016.09.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2016] [Revised: 08/13/2016] [Accepted: 09/02/2016] [Indexed: 12/25/2022]
Abstract
The increasingly acquired resistance to vemurafenib and side effects of known inhibitors motivate the search for new and more effective anti-melanoma drugs. In this Letter, virtual screening and scaffold growth were combined together to achieve new molecules as BRAFV600E inhibitors. Along with docking simulation, a primary screen in vitro was performed to filter the modifications for the lead compound, which was then substituted, synthesized and evaluated for their inhibitory activity against BRAFV600E and several melanoma cell lines. Out of the obtained compounds, derivative 3l was identified as a potent BRAFV600E inhibitor and exerted an anticancer effect through BRAFV600E inhibition. The following biological evaluation assays confirmed that 3l could induce cell apoptosis and marked DNA fragmentation. Furthermore, 3l could arrest the cell cycle at the G0/G1 phase in melanoma cells. The docking simulation displayed that 3l could tightly bind with the crystal structure of BRAFV600E at the active site. Overall, the biological profile of 3l suggests that this compound may be developed as a potential anticancer agent.
Collapse
|
9
|
Williams TE, Subramanian S, Verhagen J, McBride CM, Costales A, Sung L, Antonios-McCrea W, McKenna M, Louie AK, Ramurthy S, Levine B, Shafer CM, Machajewski T, Renhowe PA, Appleton BA, Amiri P, Chou J, Stuart D, Aardalen K, Poon D. Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma. ACS Med Chem Lett 2015; 6:961-5. [PMID: 26396681 DOI: 10.1021/ml500526p] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2014] [Accepted: 07/20/2015] [Indexed: 01/07/2023] Open
Abstract
Abrogation of errant signaling along the MAPK pathway through the inhibition of B-RAF kinase is a validated approach for the treatment of pathway-dependent cancers. We report the development of imidazo-benzimidazoles as potent B-RAF inhibitors. Robust in vivo efficacy coupled with correlating pharmacokinetic/pharmacodynamic (PKPD) and PD-efficacy relationships led to the identification of RAF265, 1, which has advanced into clinical trials.
Collapse
Affiliation(s)
- Teresa E. Williams
- Global Discovery Chemistry,
Oncology and Exploratory Chemistry, Novartis Institutes for Biomedical Research, 5300 Chiron Way, Emeryville, California 94608, United States
| | - Sharadha Subramanian
- Global Discovery Chemistry,
Oncology and Exploratory Chemistry, Novartis Institutes for Biomedical Research, 5300 Chiron Way, Emeryville, California 94608, United States
| | - Joelle Verhagen
- Global Discovery Chemistry,
Oncology and Exploratory Chemistry, Novartis Institutes for Biomedical Research, 5300 Chiron Way, Emeryville, California 94608, United States
| | - Christopher M. McBride
- Global Discovery Chemistry,
Oncology and Exploratory Chemistry, Novartis Institutes for Biomedical Research, 5300 Chiron Way, Emeryville, California 94608, United States
| | - Abran Costales
- Global Discovery Chemistry,
Oncology and Exploratory Chemistry, Novartis Institutes for Biomedical Research, 5300 Chiron Way, Emeryville, California 94608, United States
| | - Leonard Sung
- Global Discovery Chemistry,
Oncology and Exploratory Chemistry, Novartis Institutes for Biomedical Research, 5300 Chiron Way, Emeryville, California 94608, United States
| | - William Antonios-McCrea
- Global Discovery Chemistry,
Oncology and Exploratory Chemistry, Novartis Institutes for Biomedical Research, 5300 Chiron Way, Emeryville, California 94608, United States
| | - Maureen McKenna
- Global Discovery Chemistry,
Oncology and Exploratory Chemistry, Novartis Institutes for Biomedical Research, 5300 Chiron Way, Emeryville, California 94608, United States
| | - Alicia K. Louie
- Global Discovery Chemistry,
Oncology and Exploratory Chemistry, Novartis Institutes for Biomedical Research, 5300 Chiron Way, Emeryville, California 94608, United States
| | - Savithri Ramurthy
- Global Discovery Chemistry,
Oncology and Exploratory Chemistry, Novartis Institutes for Biomedical Research, 5300 Chiron Way, Emeryville, California 94608, United States
| | - Barry Levine
- Global Discovery Chemistry,
Oncology and Exploratory Chemistry, Novartis Institutes for Biomedical Research, 5300 Chiron Way, Emeryville, California 94608, United States
| | - Cynthia M. Shafer
- Global Discovery Chemistry,
Oncology and Exploratory Chemistry, Novartis Institutes for Biomedical Research, 5300 Chiron Way, Emeryville, California 94608, United States
| | - Timothy Machajewski
- Global Discovery Chemistry,
Oncology and Exploratory Chemistry, Novartis Institutes for Biomedical Research, 5300 Chiron Way, Emeryville, California 94608, United States
| | - Paul A. Renhowe
- Global Discovery Chemistry,
Oncology and Exploratory Chemistry, Novartis Institutes for Biomedical Research, 5300 Chiron Way, Emeryville, California 94608, United States
| | - Brent A. Appleton
- Global Discovery Chemistry,
Oncology and Exploratory Chemistry, Novartis Institutes for Biomedical Research, 5300 Chiron Way, Emeryville, California 94608, United States
| | - Payman Amiri
- Global Discovery Chemistry,
Oncology and Exploratory Chemistry, Novartis Institutes for Biomedical Research, 5300 Chiron Way, Emeryville, California 94608, United States
| | - James Chou
- Global Discovery Chemistry,
Oncology and Exploratory Chemistry, Novartis Institutes for Biomedical Research, 5300 Chiron Way, Emeryville, California 94608, United States
| | - Darrin Stuart
- Global Discovery Chemistry,
Oncology and Exploratory Chemistry, Novartis Institutes for Biomedical Research, 5300 Chiron Way, Emeryville, California 94608, United States
| | - Kimberly Aardalen
- Global Discovery Chemistry,
Oncology and Exploratory Chemistry, Novartis Institutes for Biomedical Research, 5300 Chiron Way, Emeryville, California 94608, United States
| | - Daniel Poon
- Global Discovery Chemistry,
Oncology and Exploratory Chemistry, Novartis Institutes for Biomedical Research, 5300 Chiron Way, Emeryville, California 94608, United States
| |
Collapse
|
10
|
Sulzer-Mosse S, Cederbaum F, Lamberth C, Berthon G, Umarye J, Grasso V, Schlereth A, Blum M, Waldmeier R. Synthesis and fungicidal activity of N-thiazol-4-yl-salicylamides, a new family of anti-oomycete compounds. Bioorg Med Chem 2015; 23:2129-38. [DOI: 10.1016/j.bmc.2015.03.007] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2014] [Revised: 02/24/2015] [Accepted: 03/02/2015] [Indexed: 10/23/2022]
|